Latest updates for INCY PCYC SGEN BMRN CEMP CYTK CYTR EBIO EXEL KYTH LPCN LXRX MDCO NBIX NBS OCRX OGXI OPK THLD THRX TSRO

May 02, 2015 No Comments by

Latest updates to the Company Pipeline Database for April 29-May 1 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary INCY 98.28 Ruxolitinib – JANUS 1 and JANUS 2 Cancer – Pancreatic Phase 3 Phase 3 data for JANUS 1 due 2016. JANUS 2 due at a later date PCYC 254.51 IMBRUVICA […]

Daily News Read more

SHPG PDUFA date set. EXEL data due 2H 2015. DERM initiates Phase 2 acne trial.

Apr 10, 2015 No Comments by

Latest updates to the Company Pipeline Database for April 9. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary DERM 15.15 DRM01 Acne Phase 2b Phase 2b initiated April 2015. Data due 1H 2016 EXEL 3.01 Cabozantinib – (METEOR) Cancer – metastatic renal cell cancer (RCC) Phase 3 Data due 2Q 2015 […]

Daily News Read more

Pipeline updates for ALKS ARDX ATRS BMRN CEMP CLDX CLVS DPRX DYAX EXEL FLXN INFI NKTR TBPH XOMA

Feb 26, 2015 No Comments by

Latest updates to the Company Pipeline Database for February 24-25, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ALKS 71.11 ALKS 5461 Major depressive disorder Phase 2 Phase 3 (two trials) initiated Jun 2014. Data due 2016. Third Phase 3 trial initiated mid 2014. Data due […]

Daily News Read more

Updates for week ending February 20

Feb 20, 2015 No Comments

Latest updates to the Company Pipeline Database for week ending February 20, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AGIO 106.30 AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 trial to be initiated 1H 2015 2/21/2015 ARIA 8.06 Brigatinib – ALTA trial Anaplastic lymphoma kinase […]

Read more

Pipeline updates for ACOR BLRX EXEL RARE SPHS LPCN VBLT ZFGN

Dec 16, 2014 No Comments

Latest updates to the Company Pipeline Database from December 15 2014. Refer to the FDA Calendar for upcoming catalysts Ticker Price Drug Indication Stage Link Text Updated ACOR 38.4 Dalfampridine Post stroke deficits Phase 2b/3 Annonuced Dec 15, 2015 that a Phase 3 trial has been initiated 12/16/2014 BLRX 1.63 BL-8040 Cancer – Acute myeloid leukemia […]

Read more

EXEL fails Phase 3 COMET-2 trial + updates for CANF FLXN GLMD QURE NKTR

Dec 02, 2014 No Comments

Latest updates to the Company Pipeline Database from December 1 2014: Ticker Price Drug Indication Stage Notes Updated CANF 4.45 CF101 Psoriasis Phase 2/3 Phase 2/3 topline data due 1Q 2015 12/2/2014 CANF 4.45 CF101 Rheumatoid arthritis Phase 3 Phase 3 planned 12/2/2014 CANF 4.45 CF101 Glaucoma Phase 2 Phase 2 data due 2Q or […]

Read more

EXEL Phase 3 data due 2Q 2015 + upcoming catalyst dates for XNPT IRWD ACHN AQXP + LXRX XOMA updates

Nov 04, 2014 No Comments

Exelixis, Inc. (NASDAQ:EXEL) provided an update noting that top-line results from their pivotal Phase 3 trial METEOR in metastatic renal cell carcinoma, are now anticipated in 2Q 2015. XenoPort, Inc. (Nasdaq: XNPT) provided an update noting that top-line data from their Phase 2 XP23829 trial as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and/or relapsing forms of […]

Read more

EXEL Phase 3 COMET-1 trial fails to meet primary endpoint.

Sep 02, 2014 No Comments

Exelixis, Inc. (NASDAQ:EXEL) announced that it did not meet the primary endpoint following release of top-line results from their Phase 3 COMET-1 of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The median OS for the cabozantinib arm of the trial was 11.0 […]

Read more

TRGT fails Phase 2b. Positive news for SLXP PGNX EXEL. Phase 3 data due soon for ADHD ZSPH + AERI SGYP VTUS ANTH GNCA updates

Jul 15, 2014 No Comments

Targacept, Inc. (NASDAQ: TRGT) announced that it did not meet the primary endpoint in their Phase 2b monotherapy trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals(NASDAQ:PGNX) announced that the FDA has informed Salix that RELISTOR Subcutaneous Injection, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic […]

Read more

INSM data due today. CYCC topline Sapacitabine data due 2015. EXEL data due later this year + BIND EVOK ECYT news

Mar 26, 2014 No Comments

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) said it expects to complete enrolment in their Phase 3 SEAMLESS trial of Sapacitabine in patients with acute myeloid leukemia (AML). Topline data are due in 2015. Insmed Incorporated (NASDAQ: INSM) will announce results from its U.S. phase 2 clinical trial of ARIKAYCE, to treat nontuberculous mycobacteria (NTM) lung infections on Wednesday, March 26, 2014 at approximately 7:00 a.m. […]

Read more

BDSI ENDP Phase 3 endpoint met. PGNX ATOS TXNP DSCI to raise cash. EXEL XNPT price offerings. APPA NASDAQ uplist + CYTR

Jan 24, 2014 No Comments

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) filed a $150m shelf and also noted that it has entered into a sales agreement where up to $50m of common stock may be issued and sold under a sales agreement with Cantor Fitzgerald & Co. Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced that it intends to offer shares of its common stock in an […]

Read more